Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$3.57
+5.0%
$4.74
$3.35
$22.00
$92.36MN/A82,409 shs81,122 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$5.82
+4.9%
$6.17
$5.41
$23.48
$503.87M0.51.43 million shs1.15 million shs
Prothena Co. plc stock logo
PRTA
Prothena
$4.70
+2.2%
$9.21
$4.32
$25.42
$252.99M0.11680,522 shs5.38 million shs
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
$14.11
+10.8%
$11.68
$7.26
$25.19
$622.59MN/A187,704 shs127,083 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-3.13%-11.92%-24.44%-52.38%-76.87%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-1.07%-10.48%-14.75%-27.45%-74.17%
Prothena Co. plc stock logo
PRTA
Prothena
+0.44%-32.55%-52.33%-69.60%-76.94%
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-2.68%-5.70%+5.73%-13.75%+1,272,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
1.9571 of 5 stars
3.62.00.00.02.30.80.6
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.4166 of 5 stars
4.52.00.04.73.20.80.6
Prothena Co. plc stock logo
PRTA
Prothena
2.67 of 5 stars
4.21.00.00.02.11.71.3
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.20
Buy$22.50530.25% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.93
Moderate Buy$24.50320.96% Upside
Prothena Co. plc stock logo
PRTA
Prothena
2.33
Hold$31.50570.21% Upside
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
3.00
Buy$38.50172.86% Upside

Current Analyst Ratings Breakdown

Latest CTNM, KURA, SION, and PRTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Prothena Co. plc stock logo
PRTA
Prothena
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underperform
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $14.00
5/27/2025
Prothena Co. plc stock logo
PRTA
Prothena
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $18.00
5/19/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.00
5/19/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/15/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M1.85$0.56 per share6.35($3.72) per share-0.96
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.99M7.41N/AN/A$5.35 per share1.09
Prothena Co. plc stock logo
PRTA
Prothena
$137.94M1.83N/AN/A$10.46 per share0.45
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$22.72M-$1.97N/AN/AN/AN/A-49.92%-20.52%8/12/2025 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%8/14/2025 (Estimated)
Prothena Co. plc stock logo
PRTA
Prothena
-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/14/2025 (Estimated)
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A

Latest CTNM, KURA, SION, and PRTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
5/12/2025Q1 2025
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-$0.45-$0.62-$0.17-$0.62N/AN/A
5/8/2025Q1 2025
Prothena Co. plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
3/20/2025N/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-$2.68-$3.38-$0.70-$3.38N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Prothena Co. plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
37.06
37.06
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
11.47
11.47
Prothena Co. plc stock logo
PRTA
Prothena
N/A
11.52
11.52
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Prothena Co. plc stock logo
PRTA
Prothena
97.08%
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6.40%
Prothena Co. plc stock logo
PRTA
Prothena
9.20%
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3125.87 millionN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.58 million73.49 millionOptionable
Prothena Co. plc stock logo
PRTA
Prothena
13053.83 million38.64 millionOptionable
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
3544.12 millionN/AN/A

Recent News About These Companies

2025 Power 100: Mike Cloonan
Two more biotechs join IPO waiting list
Sionna Therapeutics, Inc. (SION) Gets a Buy from TD Cowen
Sionna Therapeutics Inc.
Sionna Therapeutics sees cash runway into 2028

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$3.57 +0.17 (+5.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.59 +0.02 (+0.56%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$5.82 +0.27 (+4.86%)
Closing price 04:00 PM Eastern
Extended Trading
$5.82 0.00 (-0.09%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Prothena stock logo

Prothena NASDAQ:PRTA

$4.70 +0.10 (+2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$4.66 -0.04 (-0.74%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Sionna Therapeutics stock logo

Sionna Therapeutics NASDAQ:SION

$14.11 +1.38 (+10.84%)
As of 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.